Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(24):1811-1812; doi:10.1093/jnci/djg133
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Pater, J. L.
Right arrow Articles by Parulekar, W. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pater, J. L.
Right arrow Articles by Parulekar, W. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

EDITORIAL

Ovarian Ablation as Adjuvant Therapy for Premenopausal Women With Breast Cancer—Another Step Forward

Joseph L. Pater, Wendy R. Parulekar

Affiliation of authors: National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada.

Correspondence to: Joseph L. Pater, MD, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada K7L 3N6 (e-mail: jpater@ctg.queensu.ca)

The first 10% of the full text of this article appears below.

The role of ovarian suppression in the management of localized, newly diagnosed breast cancer in premenopausal women has been the subject of controversy for some time (1). In this issue of the Journal, results from an International Breast Cancer Study Group (IBCSG) trial (2) that addresses this question add further support for the use of ovarian suppression. However, as the authors imply, the results are best seen as a step in the pathway to the delineation of the true value of ovarian suppression in contemporary patient management.

The IBCSG trial compared, in a group of 1063 premenopausal patients, three treatment strategies: 1) . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
S. Dellapasqua, M. Colleoni, R. D. Gelber, and A. Goldhirsch
Adjuvant Endocrine Therapy for Premenopausal Women With Early Breast Cancer
J. Clin. Oncol., March 10, 2005; 23(8): 1736 - 1750.
[Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
G S Harrison, M E Wierman, T M Nett, and L M Glode
Gonadotropin-releasing hormone and its receptor in normal and malignant cells
Endocr. Relat. Cancer, December 1, 2004; 11(4): 725 - 748.
[Abstract] [Full Text] [PDF]